An artery is not a pipe. It bends. It pulses. Its diameter changes as blood moves through it. Yet one of cardiology's standard mechanical answers to a narrowed artery has been a tiny metal cage designed to remain rigid. Motasim Sirhan knew the logic from the inside. Early in his career at Guidant Corporation, he worked on catheter systems and interventional technologies, including the RX Perfusion Catheter, PET balloon technology, and the Multi-Link stent. The devices opened blocked vessels. They also fixed the industry's central metaphor: restore flow by building a scaffold that does not yield.
Sirhan made a career from that craft before he began to challenge it. He left Guidant, founded Avantec Vascular, and exited the company after its acquisition in 2002. He co-founded Maya Medical. Then, in 2005, he started Elixir Medical in Milpitas with colleagues who had also lived inside vascular engineering. His question was pointed: could an implant do the early job of a stent without asking the artery to surrender its motion forever?
The useful discomfort of an insider
Sirhan describes himself plainly as an engineer by training. His education at the University of Southern California combined biomedical and electrical engineering with a master's degree in management. The mix is visible in the company he built. Elixir's work sits where mechanics, polymers, pharmacology, manufacturing, trials, and regulation meet. Any one discipline can ruin the others if it arrives late.
The original irritation was clinical and structural. A drug-eluting stent can reopen an artery and deliver medicine that limits tissue growth around the implant. But the metal stays, and adverse events can continue after the first year. Sirhan wanted to treat the immediate blockage while addressing what permanent caging does to the vessel's natural behavior. He did not arrive at that position as an outside critic. He had helped develop the products that made the existing approach work.
“It has always bothered me that with stents, regardless of generation, we have not been able to improve outcomes beyond one year of the procedure.”Motasim Sirhan, 2025
That sentence contains both his advantage and his burden. Experience gave him a specific complaint. It also denied him the luxury of a vague solution. Any alternative had to deliver through familiar catheter procedures, produce enough radial strength to hold an artery open, control drug release, survive manufacturing, and withstand clinical comparison with mature stents.
Locked support
Three helical elements act together while the vessel begins to heal.
Polymer resorbs
The coating that holds the implant together gradually disappears.
Dynamic support
The strands separate so the artery can pulse and adapt while support remains.
A pivot hidden inside a polymer
Elixir did not travel directly from complaint to DynamX. The company first pursued fully bioresorbable scaffolds, an approach built around leaving no permanent implant after the scaffold dissolved. It was an appealing endpoint. It was not, in Sirhan's view, the complete answer. The team concluded that an artery still needed continuing support after the initial healing period, but support that could move with it.
The distinction changed the product. Instead of making everything vanish, Elixir designed three 71-micron cobalt-chromium helical elements, temporarily held in a circular form by a drug-eluting, bioresorbable polymer coating. During the early phase, the elements work together. As the coating resorbs over roughly six months, the helices unlock and separate. The metal remains, but its geometry changes from a fixed cage into strands intended to accommodate pulsatility, compliance, and adaptive remodeling.
Iteration is often presented as velocity. Here it meant repeated mechanical correction. Delivery, expansion, polymer behavior, strand geometry, strength, and manufacturability had to agree before a patient could enter the picture.
Sirhan has said the technology passed through more than 150 bench iterations. The number is striking because this was hardware with biological consequences. A software patch can reach users tonight. A Class III implant earns progress in longer units: a test fixture, an animal study, a protocol, a patient enrolled, a follow-up completed. The product matured while the company waited for evidence that could not be hurried.
The founder's long clock
Elixir's story now stretches across two decades. The firm was founded in 2005. DynamX received a European CE Mark, entered randomized clinical studies, and won FDA Breakthrough Device Designation for a coronary indication in 2024. Through 2025 and 2026, Elixir continued presenting trial and real-world registry data. Each milestone represented movement, but none permitted the company to skip the next gate.
Learn the existing system
Catheters, balloons, and the Multi-Link stent at Guidant.
Exit the first company
Avantec Vascular is acquired after Sirhan's first founder chapter.
Start Elixir Medical
A new team begins combining implants, polymers, and pharmaceuticals.
Reach a regulatory milestone
FDA grants DynamX Breakthrough Device Designation for a coronary indication.
Keep collecting evidence
Elixir reports early real-world Bio-RESTORE registry results at EuroPCR.
This is where Sirhan's management education may matter as much as his engineering. A medtech founder does not merely choose a design. He must keep a multidisciplinary team, investors, physicians, regulators, and trial sites moving on clocks that rarely synchronize. Elixir has credited the Invus Group for long-running financial support. Sirhan, in turn, speaks publicly in collective nouns: colleagues, engineers, investigators, research partners.
His favorite memory from the company's journey was not the initial sketch or a patent filing. It came when randomized trial results began to arrive. He recalled investigators and research partners reacting to reductions in adverse events across separate studies. After years when progress was mostly visible inside the company, the readouts made the mechanism legible to outsiders.
Evidence is the product after the product
A medical implant carries two stories. The first is how it is supposed to work. The second is what happened after clinicians used it. Founders control much of the first and far less of the second. That separation explains Elixir's emphasis on randomized studies and imaging, not simply demonstrations of a device unlocking on a bench.
In 2024, Elixir reported two-year results from the 444-patient BIOADAPTOR randomized trial. In its per-protocol analysis of patients with new lesions, the company reported target lesion failure of 1.9 percent for DynamX and 5.5 percent for a contemporary drug-eluting stent. A separate 2,400-patient INFINITY-SWEDEHEART randomized study met its primary non-inferiority endpoint at one year. Those figures come with protocols, patient populations, endpoints, and follow-up periods. They are not a universal promise. They are the structured argument a regulated device must make.
Breakthrough designation also requires careful reading. It offers a path for more intensive FDA interaction and expedited review for qualifying devices. It is not U.S. market approval. Sirhan's stated goal in 2025 was to begin U.S. trials for DynamX and Elixir's LithiX system and move toward market access through the required clinical and regulatory process. The ambition remains tied to a sequence of proofs.
A portfolio built from root problems
DynamX is the center of Sirhan's public story, but Elixir's portfolio reveals how he frames problems. LithiX targets calcified lesions through a mechanical, contact-based approach that does not require an external energy generator. TRx is a site-specific antithrombotic platform. A below-the-knee DynamX system extends bioadaptive support into peripheral vessels. The common thread is not a single component. It is the attempt to remove a compromise that has become routine.
Sirhan contrasts a focused company with large medical-device businesses that must manage broad portfolios and protect existing franchises. His argument is practical: a smaller team can concentrate diverse expertise on the root of one problem. But focus does not erase constraints. Elixir still has to manufacture reliably, fund trials, secure approvals, earn physician confidence, and show that a novel mechanism improves outcomes outside controlled studies.
“Developing Class III medical devices is a complex process and requires expertise, agility, and perseverance.”Motasim Sirhan, reflecting on Elixir's pivots
Perseverance is an easy word to print on a company wall. Elixir's version is more specific. It includes admitting that a fully disappearing scaffold was not enough, preserving the part of the implant that still had a job, and redesigning how that metal behaved. It includes running another bench test after the hundredth. It includes letting investigators determine whether the design story survives contact with clinical evidence.
The pattern beneath the patents
Elixir's official biography names Sirhan as inventor or co-inventor on 35 patent or patent-pending applications. Patent records trace his work from a perfusion-type dilatation catheter filed in 1992 through drug-delivery implants at Avantec and later vascular devices at Elixir. The filings show continuity: delivery through narrow anatomy, mechanical support, and the controlled release of therapeutic agents.
They also show how rarely invention belongs to one person. Names such as John Yan, Vinayak Bhat, Howard Huang, and other collaborators recur. Sirhan co-founded Elixir with engineers he had worked beside before. That continuity is a useful counterweight to the solitary-founder myth. Complex hardware is institutional memory made physical. Teams learn together, carry a vocabulary between companies, and recognize which old compromises deserve another look.
The public glimpses outside the laboratory are small but consistent. In 2015, a Stanford student group invited Sirhan to speak in a series about Arab leaders in Silicon Valley and described his run of biomedical startups. In 2026, Elixir said he matched its employee backpack-drive goal two to one, adding $6,000 to a local school-supply campaign. Neither item explains the bioadaptor. Together they place the engineer in a community: teaching the founder story, then quietly multiplying a team effort.
Give the vessel its future back
Sirhan's career has a satisfying circularity. He learned to make arteries stay open. He built and sold a company around vascular devices. Then he returned to the same anatomy with a different measure of success. Blood flow still matters immediately. Elixir's wager is that motion and function matter over the years that follow.
The lesson for builders is not to reject the standard because it is old. Sirhan's path suggests something more disciplined: learn why the standard won, identify the price it continues to charge, and construct evidence for a better trade. The 150 iterations are part of that evidence. So are the pivot, the randomized trials, the regulatory designation, and the registry that continues to enroll patients.
At LSI USA in 2024, Sirhan introduced Elixir's work as a story of persistence, commitment, and passion. The words could have floated away as conference language. His record gives them ballast. Nearly two decades after Elixir began, the company is still testing whether an artery can receive structure without losing its capacity to behave like an artery. Sirhan's longest project is built around a modest mechanical gesture: hold on when support is needed, then loosen your grip.